NCT04091360View on ClinicalTrials.gov

A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

December 10, 2020

Study Completion Date

January 21, 2021

Conditions
COPD
Interventions
DRUG

Part A: RPL554

Single dose RPL554 via metered dose inhaler.

DRUG

Placebos

Part A: Single dose placebo via metered dose inhaler. Part B: Repeat doses of placebo via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.

DRUG

Part B: RPL554

Part B: Repeat doses via metered dose inhaler in crossover fashion. One dose administered twice daily over 7 days.

Trial Locations (2)

W1G 8HU

Respiratory Clinical Trials Ltd, London

M23 9QZ

Medicines Evaluation Unit Limited, Wythenshawe

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Verona Pharma plc

INDUSTRY

NCT04091360 - A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter